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Edited by Jesus AvilaAbstract In Alzheimer’s disease (AD), selective expression of
tau isoforms might underlie the susceptibility of diﬀerent brain
areas to develop neuroﬁbrillary tangles and this pattern might
change in the disease. In this study, we have analyzed in control
subjects and in sporadic AD patients the pattern of expression of
tau mRNA and tau proteins in areas unaﬀected (cerebellar
cortex, white matter), moderately aﬀected (occipital striate
cortex, thalamus, caudate nucleus, and putamen) or strongly
aﬀected by neuroﬁbrillary tangles (temporal and frontal asso-
ciative cortex). After RT-PCR ampliﬁcation, ﬁve products
corresponding to the tau mRNAs containing exons 2 and 3,
exon 2, without exons 2 or 3, with exon 10 and without exon 10
were identiﬁed. In control subjects, these ﬁve PCR products were
present in all areas except in white matter, where transcripts with
exons 2 or exons 2 and 3 were not identiﬁed. In AD patients, the
same pattern of transcripts was observed in diﬀerent areas,
regardless of the presence of neuroﬁbrillary lesions. After
dephosphorylation of soluble tau proteins, the six tau isoforms
were identiﬁed in the same areas by immunoblotting, including in
the white matter, suggesting that most tau isoforms with exons 2
and 3 are transported along axons. The relative expression of
0N3R isoforms was higher in the temporal cortex than in the
cerebellar cortex, both in control and AD subjects. The
qualitative pattern of expression was identical in subjects with
or without an APOE4 allele. Our results suggest that splicing
regulation of the tau gene and the relative expression of tau
isoforms are not signiﬁcantly changed in sporadic cases of the
disease, although diﬀerential expression of tau isoforms in
temporal cortex might underlie this brain area susceptibility to
neuroﬁbrillary tangles formation.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Two neuropathological lesions characterize Alzheimer’s
disease (AD): senile plaques and neuroﬁbrillary tangles (NFT).
Senile plaques are composed of an extracellular core of Ab
amyloid surrounded by dystrophic neurites. NFT are consti-
tuted of bundles of abnormal ﬁlaments, called paired helical
ﬁlaments (PHF), accumulating in neurons in selected brain* Corresponding author. Fax: +32-2-5556285.
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doi:10.1016/j.febslet.2004.09.011areas. The PHF are composed of hyperphosphorylated forms
of the microtubule-associated protein tau (PHF-tau proteins).
Tau protein binds to microtubules and is involved in regula-
tion of the stability of microtubules, axoplasmic transport and
axonal diﬀerentiation. Six tau isoforms are expressed in adult
human brain by alternative mRNA splicing from a single gene
localized on chromosome 17 and containing 16 exons. These
isoforms range from 352 to 441 amino acids in length and
diﬀer from each other by the presence or absence of three in-
serts encoded by exons 2, 3 and 10. The amino-terminal half of
tau does not contain an insert (0N tau isoforms), or contains
either an insert of 29 amino acids (encoded by exon 2, 1N tau
isoforms), or 58 amino acids insert (encoded by exons 2 and 3,
2N tau isoforms). The carboxyl-terminal half of tau contains
three or four semi-homologous repeats of 31 or 32 amino acids
(encoded by exon 10, 3R or 4R tau isoforms) corresponding to
microtubule-binding domains (for review, see [1,2]). These six
tau isoforms have been identiﬁed in PHF extracted from AD
brain tissue [3,4]. The spreading of NFT pathology in AD
follows a relatively stereotyped sequence with limbic and
neocortical associative areas being heavily aﬀected at advanced
stages, but with sparing of several brain regions (e.g., cere-
bellum, spinal cord) [5,6]. The detection of PHF-tau proteins
in cortical areas in AD patients by biochemical methods fol-
lows a sequence comparable to that observed in neuropatho-
logical studies [7]. In other neurodegenerative diseases
characterized by the presence of abnormal tau-positive ﬁbril-
lary inclusions (tauopathies), the distribution of these cellular
inclusions follows a diﬀerent neuroanatomical pattern. These
tau positive inclusions are composed of only selected tau iso-
forms, e.g., 3R tau isoforms in Pick’s disease [1] or 4R tau
isoforms in argyrophilic grain disease [8,9].
The pattern of expression of tau mRNAs and tau proteins in
diﬀerent human brain areas could underlie the propensity of
these areas to develop or not neuroﬁbrillary lesions and could
explain the formation of tau aggregates formed of selected tau
isoforms in diﬀerent tauopathies. In addition, pathological
changes in tau isoforms composition in selected brain areas
could be instrumental in the induction of tau neuroﬁbrillary
lesions. For instance, some missense or silent mutations in
exon 10 or in the intron following exon 10 (50 splice site mu-
tations), identiﬁed in familial forms of frontotemporal de-
mentias and in other tauopathies [10,11], either increase the
alternative splicing of exon 10, resulting in overproduction of 4
repeat tau mRNA and tau isoforms [12], or alter this splicing
leading to an increase in three repeat tau isoforms [13]. Theblished by Elsevier B.V. All rights reserved.
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leading to developmental changes in tau isoforms expression
[14,15]. However, only partial information is available on the
distribution of tau transcripts and normal tau protein isoforms
in the adult human brain. This study was thus aimed at in-
vestigating in parallel the distribution of tau mRNAs and tau
protein isoforms in several neuroanatomically deﬁned human
brain areas, both in control subjects and in sporadic AD cases,
in areas developing or not neuroﬁbrillary lesions in the course
of the disease.2. Materials and methods
2.1. Human brain tissue
Human brains were obtained postmortem from ﬁve control indi-
viduals without neurological disease and from ﬁve patients with a di-
agnosis of probable or possible Alzheimer’s disease (Table 1). These
patients had no history of familial transmission of the disease. The
mean age (P ¼ 0.11) and postmortem intervals (P ¼ 0.55) were not
signiﬁcantly diﬀerent between the two groups (Student’s t test). One
hemisphere was cut into 1.5 cm thick slices in the frontal plane and
dipped in liquid N2. These tissues were stored at )80 C until use. The
other hemisphere was ﬁxed in 10% formalin. The neuropathological
analysis showed the presence of numerous senile plaques and neuro-
ﬁbrillary tangles in patients with Alzheimer’s disease and they were
graded as stages V–VI (four cases) and III–IV (one case) for neuroﬁ-
brillary degeneration according to the staging of [5].
2.2. RNA isolation
Samples of gray matter from the temporal cortex (inferior temporal
gyrus), frontal cortex (inferior frontal gyrus), occipital cortex (gyrus
lingula), caudate nucleus, putamen, thalamus, neocerebellar cortex and
from the white matter (centrum semiovale) were dissected from the
frozen tissues slices for RNA isolation. To assess the presence of NFT
and amyloid deposits, small tissue blocks immediately adjacent to these
samples were also dissected and ﬁxed in formalin for immunohisto-
chemical analysis (see below). For total RNA isolation, tissue samples
(100 mg) were homogenized without prior thawing in RNase-free
Teﬂon/glass homogenizers with 1 ml of TRIZOL Reagent (Invitrogen)
and the homogenates were extracted by adding 0.2 ml of chloroform
followed by centrifugation at 12 000· g for 15 min at 4 C. The upper
aqueous phase was kept and 0.5 ml of isopropyl alcohol was added to
precipitate RNA. After centrifugation, the pellet was washed with 1 ml
of 75% (v/v) ethanol, dried and dissolved in RNase free water. Elec-
trophoresis of RNA preparations on RNase free 1% agarose gel was
used to assess RNA integrity (presence of non-degraded 18S and 28S
ribosomal RNA). RNA concentration was measured by absorbance
reading at 260 nm and the RNA samples were stored at )80 C.
2.3. DNA isolation
Genomic DNA was extracted from tissue samples of the temporal
cortex. 100 mg of tissue was homogenized in 0.5 ml of extraction buﬀer,
using a glass-Teﬂon homogenizer and addition of 5 ll of ribonuclease ATable 1
Clinical and pathological data of human subjects used in this study
Cases No. Age Sex
Control 1 61 M
2 65 M
3 72 M
4 77 F
5 67 M
Mean±S.E.M. 68.4± 2.8
AD 6 72 F
7 70 F
8 71 M
9 91 F
10 84 M
Mean±S.E.M. 77.6± 4.2(RNAse A) (100 lg/ml). The homogenates were incubated for 1 h at 37
C, then added with 10 ll of proteinase K (400 lg/ml). After an over-
night incubation at 55 C, samples were centrifuged at 13 000· g for 10
min and 0.5 ml of DNAZOL (Gibco-BRL) was added to 0.5 ml of
supernatants. After agitation for 30 min, samples were centrifuged at
13 000· g for 10 min and 0.5 ml of absolute ethanol was added to 0.5 ml
of supernatants, followed by centrifugation at 13 000· g for 10 min.
The pellets were washed in 0.2 ml of 70% (v/v) ethanol, dried and dis-
solved in TE. DNA concentration was measured by absorbance reading
at 260 nm and the DNA samples were stored at )80 C.
2.4. RT-PCR analysis
Analysis of tau mRNA expression by RT-PCR was performed by
using the SuperScript One-Step RT-PCR kit with Platinium Taq Sys-
tem (Invitrogen). Single strand cDNA synthesis and PCR were per-
formed in a single tube using speciﬁc tau primers and 3 lg of total
RNA. For ampliﬁcation of the 50 half portion of tau mRNAs, the
cDNAs were ampliﬁed by using the tau1 (forward) primer localized in
exon 1 (50-ATGGCTGAGCCCCGCCAGGAG-30) and the tau4
(reverse) primer that spans exons 7 and 9 (50-TGGAGGTTCACCA-
GAGCTGGG-30). These tau primers allow for the simultaneous
ampliﬁcation of tau sequences with exons 2 and 3, exon 2 alone, or
without these exons. Two primers were also designed to amplify the 30
half portion of tau mRNAs: the tau3 primer that spans exons 7 and 9
(50-CCCAGC TCTGGTGAACCTCCA-30) and the tau2 primer lo-
calized in exon 13 (50-TCACAAACCCTGCTTGGCCAG-30). These
tau primers allow for the simultaneous ampliﬁcation of tau sequences
with or without exon 10. The PCR was performed with a predenatur-
ation step (55 C for 30 min, then 94 C for 2 min) followed by am-
pliﬁcation steps carried out over 40 cycles (denaturation, 94 C for 15 s;
annealing, 60 C for 30 s; extension, 72 C for 60 s) and a ﬁnal extension
at 72 C for 5 min. A RT-PCR for human b-actin (sense primer:
50-CCTCGCCTTTGCCGATCC-30; anti-sense primer: GGATCTT-
CATGAGGTAGTGAGTC-30) was performed in parallel for nor-
malization purposes. Products of RT-PCR were analysed by
electrophoresis on 2% agarose gel in TAE and 12% polyacrylamide gel
in TBE (0.0089 M Tris-base, 0.0089 M boric acid and 0.002 M EDTA,
pH 8.0). The DNA bands were visualized by incubating gels with
ethidium bromide for 10 min, and the gels were photographed using a
digital camera.
2.5. PCR and restriction of ampliﬁed APOE gene
The APOE genotyping was performed using DNA samples extracted
from control and AD cases brain tissue. The PCRs were carried out
with the forward primer 50-ACAGAATTCGCCCCG GCC TGGTA-
CAC-30 and the reverse primer 50-TAAGC TTGGCACGGCTGTC-
CAAGGA-30, as described [16]. Each reaction mixture was heated at 95
C for 5 min for denaturation, and subjected to 30 cycles of ampliﬁ-
cation by primer annealing (60 C for 1 min), extension (70 C for 2
min), and denaturation (95 C for 1 min). The PCR product of APOE
gene ampliﬁcation was digested with 5 units of HhaI for each reaction
mixture (3 h at 37 C). The digestion products were analysed by elec-
trophoresis on 8% polyacrylamide gel in TBE.
2.6. Preparation of tau proteins
Brain tissue samples (from the same dissected blocks as those used
for RNA isolation) from controls subjects and Alzheimer disease pa-Postmortem delay NFT staging ApoE genotyping
8 0 3/3
4.5 0 2/3
24 0 3/3
48 0 3/4
24 I–II 3/3
21.7± 7.7
24 V–VI 3/3
21 V–VI 3/3
24 III–IV 3/4
5.5 V–VI 3/4
7 V–VI 3/3
16.3± 4.1
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lino)ethanesulfonic acid (MES), pH 6.5, added with protease inhibitors
(leupeptin (1 lg/ml), pepstatin (1 lg/ml), soybean trypsin inhibitor (1
lg/ml), and aprotinin (1 lg/ml) (Roche). The homogenates were cen-
trifuged at 300· g for 5 min at 4 C and the supernatants used for
analysis of total tau proteins. For analysis of soluble tau proteins, these
supernatants were centrifuged at 20 000· g for 30 min at 4 C and
further centrifuged at 100 000· g for 1 h at 4 C. These high-speed
supernatants containing soluble tau proteins were further enriched in
tau proteins by treatment with 2.5% (v/v) perchloric acid for 15 min on
ice, followed by centrifugation for 20 min at 20 000· g. The ﬁnal su-
pernatants containing soluble tau protein were dialyzed against 50 mM
Tris–HCl, pH 7.4, 1 mM dithiothreitol (DTT), and 0.1 mM phenyl-
methylsulfonyl ﬂuoride (PMSF) overnight at 4 C.
2.7. Dephosphorylation of tau
Human tau preparations in 50 mM Tris–HCl, pH 7.5, were
dephosphorylated with 20 U/ll lambda phosphatase (New England
Biolabs) for 3 h at 30 C, as previously described [17]. The reaction was
stopped by the addition of 5· (SDS–PAGE) sample buﬀer and heating
for 5 min at 100 C.
2.8. Western blotting
The products of dephosphorylation of tau proteins were separated
by electrophoresis on 12% (w/v) polyacrylamide gels and proteins were
transferred onto nitrocellulose membranes. For immunoblotting, the
nitrocellulose sheets were blocked in semi-fat-dried milk (10% (w/v) in
Tris-buﬀered saline; TBS) for 1 h and incubated with primary anti-
bodies overnight, followed by anti-rabbit or anti-mouse immuno-
globulins conjugated to alkaline phosphatase (Sigma). Finally, the
membranes were incubated in developing buﬀer (0.1 M Tris–HCl, 0.1
M NaCl, and 0.05 M MgCl2, pH 9.5) containing nitroblue tetrazolium
and 5-bromo-4-chloro-3-indolyl phosphate. The densitometry analysis
of immunoblots was performed using the NIH Image J program.
Statistical analysis was performed using the Prism 4 software
(Graphpad): diﬀerences among group means were calculated by one
way analysis of variance and diﬀerences between individual groups
were estimated by Bonferroni post hoc test for multiple comparisons.
2.9. Antibodies
The B19 antibody is a rabbit polyclonal antibody raised to adult
bovine tau proteins [18]. This antibody reacts with all human and
rodent tau isoforms in a phosphorylation-independent manner. BR10
is a polyclonal antibody raised to a synthetic peptide, speciﬁc for the
insert 2 (encoded by exon 3) of tau [19]. The anti-Ab amyloid antibody
was purchased from Bio-Source.
2.10. Recombinant tau protein
Competent E. coli BL21-DE3 cells were transformed with a 2N4R
pET30a tau plasmid and recombinant 2N4R tau protein was prepared
as reported [20]. Induction of tau expression was performed by adding
IPTG (0.5 mM ﬁnal concentration) for 2 h at 37 C. Bacteria were
centrifuged for 15 min at 3300· g, the pellet was washed with 50 mM
MES, pH 6.5, and homogenized in 50 mM MES, pH 6.5, 1 mM DTT,
1 mM PMSF, 1 mM EDTA, 10 mM NaF, and 20 mM sodium py-
rophosphate by sonication on ice, followed by centrifugation at
20 000· g for 15 min at 4 C. The supernatant was adjusted to 0.5 M
NaCl, heated for 10 min, and centrifuged for 2 h at 50 000· g. The
supernatant was added with ammonium sulfate to obtain a 45% con-
centration, mixed on ice for 1 h to precipitate proteins and centrifuged
for 20 min at 30 000· g. After centrifugation, the pellet was dissolved
in a small volume of dialysis buﬀer (50 mMMES, pH 6.5, 1 mM DTT,
and 1 mM PMSF) and dialyzed overnight.Fig. 1. Immunohistochemical labeling on tissue sections of the tem-
poral cortex of (A) a control subject (Table 1, case no. 3), and (B and
C) an AD patient (Table 1, case no. 10) with the B19 tau antibody (A
and B) and the Ab antibody (C). These tissue slides were adjacent to
tissue blocks used for RNA extraction. Scale bar: 100 lm.3. Results
3.1. Concentration of total RNA is similar in areas with or
without NFT
The total RNA concentrations were not signiﬁcantly diﬀer-
ent between control (159.0–283.0 lg RNA/g tissue) and AD
subjects (148.5–263.7 lg RNA/g tissue) in all the investigated
brain areas (two-way ANOVA, P ¼ 0.10), a result consistentwith previous reports, e.g. [21,22]. The immunohistochemical
analysis of tissue blocks adjacent to those used for RNA iso-
lation conﬁrmed the presence of numerous NFT in the frontal
and temporal cortex of AD patients (Fig. 1) and their absence
in control subjects. In AD patients, a moderate number of
NFT were also detected in thalamic nuclei and a few NFT
were observed in the caudate nucleus and the putamen. NFT
were not detected in the cerebellar cortex of both AD and
control subjects.
3.2. RT-PCR ampliﬁcations of the 50 domain of tau mRNAs
identify the same products in aﬀected and non-aﬀected
areas in control subjects and AD patients
The use of primers tau1 and tau4 predicted the ampliﬁcation
of three fragments corresponding to PCR products of 393 bp
(0N tau mRNAs), 480 bp (1N tau mRNAs) and 567 bp (2N
tau mRNAs).
Fig. 2 shows the typical results of RT-PCR ampliﬁcations
from samples of the cerebellar cortex and from the temporal
cortex in ﬁve control cases (Fig. 2A) and in ﬁve AD cases
Fig. 2. Electrophoresis of RT-PCR ampliﬁcation products of the 50 domain of tau mRNAs (A and B), of the 30 domain of tau mRNAs (C and D) and
of actin mRNA (E and F) in the cerebellar cortex (c) and in the temporal cortex (t) in ﬁve control subjects (A, C, E, case nos. 1–5 in Table1) and in
ﬁve AD patients (B, D, F, case nos. 6–10 in Table 1). The three PCR products in A and B correspond to tau mRNAs with exons 2 and 3 (2N), exon 2
(1N), or without these exons (0N). The two PCR products in C and D correspond to tau mRNAs with (4R) or without exon 10 (3R). Numbers on the
left of lanes 1 indicate the position of calibration DNA fragments (in bp).
Fig. 3. Electrophoresis of RT-PCR ampliﬁcation products of the 50
domain of tau mRNAs (A and D), of the 30 domain of tau mRNAs (B
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abundant than the 567 bp PCR product, but the three PCR
products were present in all samples. Fig. 3A and D shows that
these three PCR products were also present in the frontal
cortex (lanes 3), the occipital cortex (lanes 4), the caudate
nucleus (lanes 5), the putamen (lanes 6) and in the thalamus
(lanes 7), both in control subjects (Fig. 3A) and in AD patients
(Fig. 3D). However in white matter, only the shortest 393 bp
product was detected (lanes 8).
3.3. RT-PCR ampliﬁcations of the 30 domain of tau mRNAs
identify the same products in aﬀected and non-aﬀected
areas in control subjects and AD patients
The use of primers tau3 and tau2 predicted the ampliﬁcation
of two fragments corresponding to PCR products of 686 bp
(3R tau mRNAs) and 779 bp (4R tau mRNAs). Fig. 2C and D
shows the typical results of RT-PCR ampliﬁcations from
samples of the cerebellar cortex and from the temporal cortex
in ﬁve control cases (Fig. 2C) and in ﬁve AD cases (Fig. 2D).
The 686 bp PCR product was more abundant than the 779 bp
PCR product, but they were both detected in all samples in
control subjects and in AD patients. Fig. 3B and E shows that
these two PCR products were also detected in the frontal
cortex (lanes 3), the occipital cortex (lanes 4), the caudate
nucleus (lanes 5), the putamen (lanes 6), the thalamus (lanes 7)
and in the white matter (lanes 8), both in control subjects
(Fig. 3B) and in AD patients (Fig. 3E). The total levels of PCR
products showed however some variations, even taking into
account the relative levels of actin mRNA by RT-PCR am-
pliﬁcation (Figs. 2E and F, 3C and F).
and E) and of actin mRNAs (C and F) in diﬀerent brain areas in
control subjects (A, B, C; lanes 1–4: case no. 4; lanes 5–8: case no. 5)
and in AD patients (D, E, F; lanes 1-4: case no. 6; lanes 5–8: case no.
8). Lanes 1: cerebellar cortex (c); lanes 2: temporal cortex (t); lanes 3:
frontal cortex (f); lanes 4: occipital cortex (o); lanes 5: caudate nucleus
(nc); lanes 6: putamen (p); lanes 7: thalamus (th); lanes 8: white matter
(wm). Numbers on the left of lanes 1 indicate the position of calibra-
tion DNA fragments (in bp).3.4. A similar proﬁle of six tau protein isoforms is identiﬁed
after dephosphorylation in the investigated brain areas
Fig. 4 shows the pattern of soluble tau isoforms detected in
the cerebellar cortex and in the temporal cortex in four control
cases (Fig. 4A) and in four AD cases (Fig. 4D). Soluble tauproteins were prepared from tissue samples adjacent to those
used for RNA isolation and were dephosphorylated to allow
optimal separation by electrophoresis of each isoform inde-
Fig. 4. Immunoblotting of soluble tau isoforms after dephosphoryla-
tion (A, B, D and E) and of total tau proteins (C and F) in the cere-
bellar cortex (c) and in the temporal cortex (t) in four control subjects
(A–C, case nos. 2–5) and in four AD patients (D–F, case nos. 6–9). The
lane 9 in A and D corresponds to the recombinant 2N4R tau protein.
The blots in A, C, D and F were incubated with the B19 anti-tau
antibody and the blots in B and E with the exon 3 speciﬁc anti-tau
antibody (BR10). The APOE genotype of the subjects is indicated
below the lines in C and F.
Fig. 5. Densitometry analysis of soluble tau isoform expression in the
cerebellar cortex (A) and in the temporal cortex (B) in control subjects
(white columns, case nos. 2–5) and in AD patients (gray columns, case
nos. 6–9). Tau isoforms levels are expressed as relative percentage of
the mean levels ± S.E.M. (error bars). *: P<0.05 (n ¼ 4, ANOVA).
Fig. 6. Immunoblotting of soluble tau isoforms after dephosphoryla-
tion in diﬀerent brain areas in control subjects (A, lanes 1–4: case no. 4;
lanes 5–8: case no. 5) and in AD patients (B, lanes 1–4: case no. 6; lanes
5–8: case no. 8). Lanes 1: cerebellar cortex (c); lanes 2: temporal cortex
(t); lanes 3: frontal cortex (f); lanes 4: occipital cortex (o); lanes 5:
caudate nucleus (nc); lanes 6: putamen (p); lanes 7: thalamus (th); lanes
8: white matter (wm). The lane 9 in (A) corresponds to the re-
combinant 2N4R tau protein. The position of the tau isoforms in each
blot is indicated by small bars. The APOE genotype of the subjects is
indicated below the lines.
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isoform was run in parallel to allow exact identiﬁcation of the
largest tau isoform extracted from tissue samples. For the sake
of comparison, non-dephosphorylated total tau proteins from
the same samples are shown in Fig. 4C (control cases) and in
Fig. 4F (AD cases). For comparison of soluble and total tau
levels in control and AD cases, the ratio between tau immu-
noreactivity in temporal and in cerebellar cortex (all isoforms)
was calculated for each case and both for the soluble and total
tau fractions. These ratios were not statistically diﬀerent
(P ¼ 0.12, ANOVA). The six tau isoforms were identiﬁed in
all soluble fractions, with the two 1N tau isoforms being the
most abundant and the 2N4R and 2N3R tau isoforms being of
a relatively lower abundance. The two latter tau isoforms were,
however, clearly detected by the anti-exon3 tau antibody
(BR10) in control cases (Fig. 4B) and in AD cases (Fig. 4E).
The relative expression of each soluble tau isoform in the
cerebellar cortex and in the temporal cortex was estimated by
densitometry analysis in control subjects and in AD patients
(Fig. 5). The relative percentage of each tau isoform was not
statistically diﬀerent between control subjects and AD pa-tients. The 0N3R tau isoform was however more expressed in
the temporal cortex when compared to the cerebellar cortex,
both in control subjects and in AD patients (ANOVA,
P<0.05). The six tau isoforms were also identiﬁed in the
frontal cortex (Fig. 6A and B, lanes 3), the occipital cortex
(Fig. 6A and B, lanes 4), the caudate nucleus (Fig. 6A and B,
lanes 5), the putamen (Fig. 6A and B, lanes 6), the thalamus
(Fig. 6A and B, lanes 7), and in the white matter (Fig. 6A and
Fig. 7. ApoE genotyping of control subjects (lanes 1–5: case nos. 1–5)
and AD cases (lanes 6–10: case nos. 6–10) used in this study. Lanes 1
and 7 are from diﬀerent gels. PCR ampliﬁcation of the APOE gene was
followed by restriction isotyping. The sizes of the restriction fragments
are indicated on the right and the positions of the DNA calibration
fragments are indicated on the left. The APOE genotype is indicated
below the lanes. As reported, the E2 allele is characterized by 91 and 83
bp fragments, the E3 allele by the 91 bp fragment and additional 48 and
35 bp fragments, and the E4 allele by the 48 and 35 bp fragments and a
unique 72 bp fragment. The 38 bp fragment is common to all alleles.
188 A. Boutajangout et al. / FEBS Letters 576 (2004) 183–189B, lanes 8). This pattern was similar in control subjects
(Fig. 6A) and in AD cases (Fig. 6B).
3.5. APOE genotyping in control and AD subjects
To check if the distribution of tau isoforms might be de-
pendent on the expression of selected ApoE isoforms, the
APOE genotype of all subjects was determined. Ampliﬁcation
of APOE gene sequences allowed the restriction isotyping of
apolipoprotein E isoforms expressed in control subjects and
in AD patients (Table 1 and Fig. 7). In both groups, the E3
allele was the most frequent. Two AD cases and one control
subject were heterozygous for the E4 allele. The APOE ge-
notype of subjects is indicated in Figs. 4 and 6 illustrating the
tau immunoblots from diﬀerent brain regions of control and
AD subjects. The same tau mRNAs and the six tau isoforms
were identiﬁed in the diﬀerent brain regions in subjects with
or without an E4 allele or other combinations of APOE
alleles.4. Discussion
Neuroanatomical variation of tau mRNAs and tau proteins
expression in brain areas could underlie the propensity of se-
lected areas to develop or not neuroﬁbrillary lesions and this
pattern might change in AD. This study was thus aimed at
investigating the distribution of tau mRNA and tau protein
isoforms in several neuroanatomically deﬁned human brain
areas, both in control subjects and in sporadic AD cases. The
RT-PCR ampliﬁcation of the 30 domain of tau transcripts
identiﬁed two products with the expected sizes for sequences
containing exon 10 (4R tau mRNA) or without this exon (3R
tau mRNA). The eight investigated brain areas expressed 3R
and 4R tau mRNAs, consistent with previous studies [23,24].
Our study is the ﬁrst one investigating in several human brain
areas the pattern of expression of tau mRNA encoding dif-
ferent types of N-terminal inserts. The RT-PCR ampliﬁcation
identiﬁed three products with the expected sizes for transcripts
containing exons 2 and 3, exon 2 alone, or without these exons.
These three PCR products were identiﬁed in all the gray matter
areas investigated. In white matter, only the short PCR
product was abundantly ampliﬁed. Since glial cells are largely
the most abundant cell population in the white matter, it isprobable that this PCR product results from the ampliﬁcation
of mRNAs present in astrocytes and/or oligodendrocytes.
Rodent oligodendrocytes have been reported to express tau
proteins [25] and cultured rat oligodendrocytes express both
3R and 4R tau mRNA [26]. Cultured astrocytes [27] and as-
trocytes in situ [28] express tau proteins. In addition, astrocytic
and oligodendroglial ﬁbrillary inclusions immunoreactive for
tau proteins are a common pathological feature of several
tauopathies, including progressive supranuclear palsy, multiple
system atrophy, and some familial forms of frontotemporal
dementias [29]. Our results suggest that human glial cells in situ
express mainly the 0N tau mRNAs with three or four repeats.
We have, however, identiﬁed the six soluble tau protein iso-
forms in the white matter. This suggests that most of the tau
isoforms present in the white matter are transported along
axons, although some of the 0N isoforms might be synthesized
in glial cells.
The neuroanatomical distribution of tau mRNAs species
was similar in cortical areas prone to develop NFT (temporal
and frontal cortex) and in brain areas devoid of NFT in the
disease (cerebellar cortex) or less prone to develop NFT
(striate occipital cortex). This might indicate that the propen-
sity of these neocortical areas to develop NFT is not associated
to a diﬀerential expression of tau mRNAs. Diﬀerential ex-
pression of tau mRNAs in cell subpopulations is nevertheless
not excluded by these observations; e.g., the granule cells in the
hippocampus were reported to express 3R but not 4R tau
mRNAs [23]. The same tau mRNA species were expressed in
controls and in AD in areas heavily aﬀected or unaﬀected with
NFT, suggesting that the disease is not associated to qualita-
tive change in splicing events at the level of the tau primary
transcript. In previous studies, the levels of 3R and 4R tau
mRNA were not observed to be changed in the frontal cortex
of AD patients [23,30], although a relative downregulation of
3R tau mRNA and an upregulation of 4R tau in areas heavily
aﬀected with NFT (e.g., temporal and frontal cortex) has been
reported in one study [24].
We observed a pattern of six soluble tau isoforms in the
eight brain areas investigated, with the 1N tau isoforms being
systematically the most abundant, both in control and AD
subjects. A previous report also indicated that the pattern of
soluble tau isoforms in the frontal cortex was similar in control
and AD subjects [31]. We, however, observed that the 0N3R
tau isoform was signiﬁcantly more abundant in the temporal
cortex than in the cerebellum. Although the six tau isoforms
have been identiﬁed in PHF, a relative increase in 3R tau
isoforms in PHF has been reported [32,33]. The relative higher
expression of 0N3R tau in the temporal cortex might thus
underlie the susceptibility of this area to develop NFT. Since
insoluble PHF could sequester selective tau isoforms, it is not
excluded that this might have changed the relative percentage
of soluble tau isoforms present in aﬀected brain areas in AD,
by comparison with controls. However, this was not reﬂected
in the temporal cortex that showed a similar pattern of soluble
tau isoforms in control and AD subjects, suggesting that either
the patterns of insoluble and soluble tau isoforms are relatively
similar or that a pre-existing abnormal tau pattern in AD was
hidden by selective sequestration of insoluble tau leading to a
similar pattern in control and AD subjects. Lastly, the relative
abundance of tau proteins isoforms was apparently not re-
ﬂecting the relative abundance of tau RT-PCR products (e.g.,
abundance of the 0N and 3R PCR products), but the absence
A. Boutajangout et al. / FEBS Letters 576 (2004) 183–189 189of quantitative RT-PCR ampliﬁcations of each tau mRNAs
makes diﬃcult direct comparisons between tau proteins iso-
forms and their mRNAs levels.
The E4 allele of the APOE gene has been identiﬁed as a major
risk factor in familial and sporadic AD [34] and the densities of
senile plaques and NFT have been reported to be higher in pa-
tients with an E4 allele [35]. We could however not distinguish a
diﬀerent qualitative pattern of expression of tau mRNAs or tau
proteins in subjects bearing or not an E4 allele, suggesting that
the susceptibility to develop NFT in ApoE4 positive patients is
not directly related to a peculiar pattern of tau expression.
Altogether, our study suggests that the pattern of expression
of tau mRNA transcripts and tau isoforms is not signiﬁcantly
changed at the topographical level in AD and that other
mechanisms than a disequilibrium in the relative expression of
these isoforms might be operating to foster NFT formation in
sporadic cases of AD. Since our study did not investigate the
changes of tau expression at the cellular level in AD, it is
however still possible that changes in selective cell sub-
populations might not have been detected by the present
methodological approach. Although quantitative analysis of
additional brain regions will be necessary, a diﬀerential ex-
pression of tau isoforms such as the one detected for the 0N3R
isoform in the temporal cortex might be instrumental in the
molecular mechanisms leading to NFT formation in areas
susceptible to NFT formation.
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